Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer-Reference-Cited by-同舟云学术

Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer

Published:2016-05-03 Issue:4 Volume:17 Page:344-350
ISSN:1470-269X
Container-title:The Pharmacogenomics Journal
language:en
Short-container-title:Pharmacogenomics J

Author:

Gampenrieder S P,Hufnagl C,Brechelmacher S,Huemer F,Hackl H^ORCID,Rinnerthaler G,Romeder F,Monzo Fuentes C,Morre P,Hauser-Kronberger C,Mlineritsch B,Greil R

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.nature.com/articles/tpj201625.pdf

Reference58 articles.

1. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011; 29: 4286–4293.

2. Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X et al. AVEREL: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for her2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013; 31: 1719–1725.

3. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 3239–3247.

4. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666–2676.

5. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252–1260.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The EDN1 Missense Variant rs5370G > T Regulates Adaptation and Maladaptation under Hypobaric Hypoxia;International Journal of Environmental Research and Public Health;2022-09-06

2. Identification of transcriptional landscapes and functions of the inhibition of ARHGEF2 in hepatocellular carcinoma cells;2022-08-18

3. Nephrotoxicity of Anti-Angiogenic Therapies;Diagnostics;2021-04-01

4. Pharmacogenetics for severe adverse drug reactions induced by molecular‐targeted therapy;Cancer Science;2020-08-29

5. ET-1 promotes the growth and metastasis of esophageal squamous cell carcinoma via activating PI3K/Akt pathway;Translational Cancer Research;2020-05